Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Evaluation of treatment continuation with alosetron by IBS-D severity criteria.

Nicandro JP, Shin P, Chuang E.

Curr Med Res Opin. 2012 Mar;28(3):449-56. doi: 10.1185/03007995.2011.653435. Epub 2012 Feb 7.

PMID:
22313141
2.

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82.

PMID:
15290660
3.

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A.

Aliment Pharmacol Ther. 2012 Sep;36(5):437-48. doi: 10.1111/j.1365-2036.2012.05208.x. Epub 2012 Jul 10.

4.

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.

Am J Gastroenterol. 2004 Nov;99(11):2195-203.

PMID:
15555002
5.

A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme.

Miller D, Bennett L, Hollis K, Tennis P, Cook S, Andrews E.

Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.

6.

Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.

Bleser S.

Curr Med Res Opin. 2011 Mar;27(3):503-12. doi: 10.1185/03007995.2010.547933. Epub 2011 Jan 6. Review.

PMID:
21208139
7.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.

Am J Gastroenterol. 2007 Aug;102(8):1709-19. Epub 2007 May 17.

PMID:
17509028
8.

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.

PMID:
15654790
9.

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.

Arch Intern Med. 2001 Jul 23;161(14):1733-40.

PMID:
11485506
10.

Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.

Lewis JH.

Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29. doi: 10.1586/egh.09.72.

PMID:
20136586
11.

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, Gringeri L, Johanson J, Levinson L, Mula G, Poleynard G, Stoltz RR, Truesdale R, Young D; Lotronex Investigator Team.

Am J Gastroenterol. 2002 Dec;97(12):3139-46.

PMID:
12492201
12.
13.

Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.

Bellini M, Rappelli L, Blandizzi C, Costa F, Stasi C, Colucci R, Giannaccini G, Marazziti D, Betti L, Baroni S, Mumolo MG, Marchi S, Del Tacca M.

Am J Gastroenterol. 2003 Dec;98(12):2705-11.

PMID:
14687821
14.

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Lembo A, Weber HC, Farraye FA.

Drugs. 2003;63(18):1895-905. Review.

PMID:
12930162
15.

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E; Lotronex Investigator Team.

Am J Gastroenterol. 2001 Sep;96(9):2662-70.

PMID:
11569692
16.

Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?

Cash BD, Lacy BE, Rao T, Earnest DL.

Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8. Review.

PMID:
26559529
17.

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.

Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW.

Am J Gastroenterol. 2001 Feb;96(2):455-9.

PMID:
11232690
18.

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

Tack JF, Miner PB Jr, Fischer L, Harris MS.

Aliment Pharmacol Ther. 2011 Oct;34(8):868-77. doi: 10.1111/j.1365-2036.2011.04818.x. Epub 2011 Aug 24.

19.

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.

Kennedy TM, Chalder T, McCrone P, Darnley S, Knapp M, Jones RH, Wessely S.

Health Technol Assess. 2006 Jun;10(19):iii-iv, ix-x, 1-67.

20.

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.

Chang L, Tong K, Ameen V.

Am J Gastroenterol. 2010 Apr;105(4):866-75. doi: 10.1038/ajg.2010.25. Epub 2010 Mar 2.

PMID:
20197759
Items per page

Supplemental Content

Write to the Help Desk